FrancophonIA/ELRC3.0 huggingface dataset:
English: In both studies, the main measure of effectiveness was how Xoterna Breezhaler improved patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
Slovenian: V obeh študijah je bilo glavno merilo učinkovitosti bolnikovo izboljšanje forsiranega ekspiracijskega volumna (FEV1 - največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) po 26 tednih zdravljenja.
English: It works by attaching to beta-2-adrenergic receptors found in the muscles of many organs including the airways of the lungs.
Slovenian: Deluje tako, da se veže na beta2 adrenergične receptorje v mišicah mnogih organov, vključno s pljučnimi dihalnimi potmi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xoterna Breezhaler, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Xoterna Breezhaler vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What measures are being taken to ensure the safe and effective use of Xoterna Breezhaler?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xoterna Breezhaler?
English: It works by blocking some receptors called muscarinic receptors, which control the contraction of muscles.
Slovenian: Deluje tako, da zavira receptorje, imenovane muskarinski receptorji, ki nadzorujejo krčenje mišic.
English: Indacaterol is a long-acting beta-2 agonist.
Slovenian: Indakaterol je dolgodelujoči agonist beta-2 adrenergičnih receptorjev.
English: In patients with severely reduced kidney function Xoterna Breezhaler should only be used after a careful benefit-risk assessment.
Slovenian: Pri bolnikih s hudo poslabšanim ledvičnim delovanjem se sme zdravilo Xoterna Breezhaler uporabiti samo po skrbni oceni razmerja med tveganji in koristmi.
English: COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
Slovenian: Kronična obstruktivna pljučna bolezen je dolgotrajna bolezen, pri kateri so dihalne poti in pljučni mešički poškodovani ali blokirani, kar povzroča težko vdihavanje in izdihavanje zraka.
English: The reduction in the rate of exacerbations was 10 to 12% higher with Xoterna Breezhaler than with tiotropium and glycopyrronium.
Slovenian: Zmanjšanje deleža poslabšanj je bilo za od 10 do 12 % večje pri zdravilu Xoterna Breezhaler kot pri tiotropiju in glikopironiju.
English: For more information about treatment with Xoterna Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Xoterna Breezhaler preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: A risk management plan has been developed to ensure that Xoterna Breezhaler is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Xoterna Breezhaler je bil pripravljen načrt obvladovanja tveganj.
English: The effects of Xoterna Breezhaler when used to relieve symptoms of COPD were clinically meaningful.
Slovenian: Ko se je zdravilo Xoterna Breezhaler uporabljalo za lajšanje simptomov KOPB, so bili njegovi učinki klinično pomembni.
English: For practical information about using Xoterna Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Xoterna Breezhaler naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Xoterna Breezhaler is available as capsules containing a powder for inhalation can only be obtained with a prescription.
Slovenian: Zdravilo Xoterna Breezhaler je na voljo v obliki kapsul, ki vsebujejo prašek za inhaliranje, in se izdaja le na recept.
English: In the second study the average increase in FEV1 was 140 ml more with Xoterna Breezhaler than with treatment with fluticasone and salmeterol.
Slovenian: V drugi študiji je bila povprečna vrednost FEV1 za 140 ml večja pri zdravilu Xoterna Breezhaler v primerjavi s flutikazonom in salmeterolom.
English: Other information about Xoterna Breezhaler
Slovenian: Druge informacije o zdravilu Xoterna Breezhaler
English: A third study studied the effects of Xoterna Breezhaler on the rate of exacerbations (flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium (other treatments for COPD).
Slovenian: V tretji študiji so proučevali učinke zdravila Xoterna Breezhaler na delež poslabšanj (izbruhov), ki so se pri bolnikih pojavili v 64 tednih zdravljenja, v primerjavi z zdravljenjem z glikopironijem ali tiotropijem (drugima oblikama zdravljenja KOPB).
English: Xoterna Breezhaler also increased FEV1 by 70 ml more than indacaterol alone and 90 ml than glycopyrronium alone.
Slovenian: Zdravilo Xoterna Breezhaler je prav tako povečalo vrednost FEV1 za dodatnih 70 ml v primerjavi s samostojnim indakaterolom in 90 ml v primerjavi s samostojnim glikopironijem.
English: The active substances in Xoterna Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD.
Slovenian: Zdravilni učinkovini v zdravilu Xoterna Breezhaler, indakaterol in glikopironij, različno razširita dihalne poti in izboljšata dihanje pri KOPB.
English: The first study showed that treatment with Xoterna Breezhaler was more effective than placebo and increased FEV1 by an average of 200 ml more.
Slovenian: Prva študija je pokazala, da je bilo zdravljenje z zdravilom Xoterna Breezhaler učinkovitejše od placeba, saj je bila povprečna vrednost FEV1 za 200 ml večja kot pri placebu.
English: Regarding its safety, Xoterna Breezhaler is comparable to indacaterol and glycopyrronium used as separate medicines.
Slovenian: Varnost zdravila Xoterna Breezhaler je primerljiva z indakaterolom in glikopironijem, če se uporabljata kot ločeni zdravili.
English: For the full list of all side effects reported with Xoterna Breezhaler, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Xoterna Breezhaler, glejte navodilo za uporabo.
English: What is Xoterna Breezhaler and what is it used for?
Slovenian: Kaj je zdravilo Xoterna Breezhaler in za kaj se uporablja?
English: Muscarinic receptor antagonists and long-acting beta-2-adrenergic agonists are commonly combined in the management of COPD.
Slovenian: Kombinacija antagonistov muskarinskih receptorjev in dolgodelujočih agonistov beta-2 adrenergičnih receptorjev se pogosto uporablja za urejanje KOPB.
English: What benefits of Xoterna Breezhaler have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Xoterna Breezhaler izkazalo v študijah?
English: While one study compared the effects of Xoterna Breezhaler with those of placebo (a dummy treatment), or indacaterol or glycopyrronium alone, the other study compared Xoterna Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Slovenian: V eni študiji so primerjali učinke zdravila Xoterna Breezhaler z učinki placeba (zdravila brez zdravilne učinkovine) ali samostojnega indakaterola ali glikopironija, v drugi pa zdravilo Xoterna Breezhaler s kombinacijo flutikazona in salmeterola, tj. standardno obliko zdravljenja KOPB.
English: What are the risks associated with Xoterna Breezhaler?
Slovenian: Kakšna tveganja so povezana z zdravilom Xoterna Breezhaler?
English: Why is Xoterna Breezhaler approved?
Slovenian: Zakaj je bilo zdravilo Xoterna Breezhaler odobreno?
English: When glycopyrronium is inhaled, it causes the muscles of the airways to relax.
Slovenian: Ob inhalaciji glikopironij sprosti mišice v dihalih.
English: This causes the muscles of the airways to relax.
Slovenian: To sprosti mišice v dihalih.
English: How is Xoterna Breezhaler used?
Slovenian: Kako se zdravilo Xoterna Breezhaler uporablja?
English: How does Xoterna Breezhaler work?
Slovenian: Kako zdravilo Xoterna Breezhaler deluje?
English: Indacaterol / glycopyrronium
Slovenian: Xoterna Breezhaler indakaterol/glikopironij
English: Further information on Vyxeos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Vyxeos so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Vyxeos?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vyxeos?
English: Other information about Vyxeos
Slovenian: Druge informacije o zdravilu Vyxeos
English: As for all medicines, data on the use of Vyxeos are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Vyxeos stalno spremljajo.
English: The European Medicines Agency decided that Vyxeos's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Vyxeos večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: An overview of Vyxeos and why it is authorised in the EU
Slovenian: Pregled zdravila Vyxeos in zakaj je odobreno v EU
English: What benefits of Vyxeos have been shown in studies?
Slovenian: Kakšne koristi zdravila Vyxeos so se pokazale v študijah?
English: Vyxeos (daunorubicin / cytarabine) EMA/457184/2018
Slovenian: Vyxeos (daunorubicin/citarabin) EMA/457184/2018
English: Some 34% of patients given Vyxeos (52 of 153) were able to go on to have a stem cell transplant (a potentially curative procedure where the patient's bone marrow is replaced by stem cells to form new, healthy bone marrow) compared with 25% (39 of 156) given conventional treatment.
Slovenian: Približno 34 % (52 od 153) bolnikov, zdravljenih z zdravilom Vyxeos, je lahko opravilo presaditev matičnih celic (postopek zdravljenja, kjer bolnikov kostni mozeg nadomestijo z matičnimi celicami, ki tvorijo nov, zdrav kostni mozeg) v primerjavi s 25 % (39 od 156) bolnikov, ki so prejeli običajno zdravljenje.
English: The most common side effects with Vyxeos (which may affect more than 1 in 5 people) are hypersensitivity (allergic reactions, especially rash), febrile neutropenia (low white cell counts with fever), oedema (swelling), diarrhoea, colitis (inflamed bowel), mucositis (inflammation of the moist body surfaces), tiredness, muscle and bone pain, belly pain, decreased appetite, cough, headache, chills, arrhythmias (irregular heart rhythm), fever, sleep disorders and hypotension (low blood pressure).
Slovenian: Najpogostejši neželeni učinki zdravila Vyxeos (ki se lahko pojavijo pri več kot 1 od 5 bolnikov) so preobčutljivost (alergijske reakcije, zlasti izpuščaji), febrilna nevtropenija (majhno število belih krvnih celic in zvišana telesna temperatura), edem (oteklina), driska, kolitis (vnetje črevesa), mukozitis (vnetje vlažnih delov telesa), utrujenost, zmanjšan apetit, kašelj, glavobol, mrzlica, aritmija (nereden srčni utrip), zvišana telesna temperatura, motnje spanja in hipotenzija (nizek krvni tlak).
English: They interfere in different ways with the production of new DNA within cells, which means the cells are unable to grow and multiply, and they eventually die.
Slovenian: Na različne načine vplivata na nastajanje nove deoksiribonukleinske kisline (DNK) v celicah, zaradi česar celice ne morejo rasti in se razmnoževati, sčasoma pa umrejo.
English: Why is Vyxeos authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Vyxeos odobreno v EU?
English: What are the risks associated with Vyxeos?
Slovenian: Kakšna tveganja so povezana z zdravilom Vyxeos?
English: What is Vyxeos and what is it used for?
Slovenian: Kaj je zdravilo Vyxeos in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vyxeos have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Vyxeos upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Vyxeos (daunorubicin / cytarabine)
Slovenian: Vyxeos (daunorubicin/citarabin)
English: The side effects were similar to the known side effects of the active substances and were considered manageable.
Slovenian: Neželeni učinki so bili podobni znanim neželenim učinkom učinkovin in se štejejo za obvladljive.
English: Patients given Vyxeos lived on average around 9.6 months after treatment, whereas those given conventional cytarabine and daunorubicin lived about 6 months.
Slovenian: Bolniki, ki so prejemali zdravilo Vyxeos, so v povprečju živeli 9,6 meseca po zdravljenju, medtem ko so tisti, ki so prejeli običajne oblike citarabina in daunorubicina, živeli približno 6 mesecev.
English: Side effects reported with Vyxeos are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Vyxeos, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Vyxeos can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in using cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Vyxeos je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
English: For more information about using Vyxeos, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Vyxeos glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The active substances in Vyxeos, cytarabine and daunorubicin, have been used together to treat leukaemia and other types of cancer for many years.
Slovenian: Učinkovini v zdravilu Vyxeos, citarabin in daunorubicin, se že vrsto let uporabljata skupaj za zdravljenje levkemije in drugih vrst raka.
English: The liposomes protect the cancer medicines from being broken down early, which is expected to enhance their effect on cancer cells.
Slovenian: Liposomi ščitijo zdravila za zdravljenja raka, da se ne razgradijo prezgodaj, kar naj bi omogočilo boljši učinek na rakave celice.
English: Vyxeos is used when the leukaemia was caused by previous treatments (e.g. for other cancers) or is associated with certain changes in the bone marrow known as myelodysplasia.
Slovenian: Zdravilo Vyxeos se uporablja v primerih, ko je levkemija posledica predhodnih zdravljenj (npr. drugih oblik raka) ali je povezana z določenimi spremembami v kostnem mozgu, imenovanimi mielodisplazija.
English: In this medicine, cytarabine and daunorubicin are contained in tiny fat droplets called ‘liposomes'.
Slovenian: V tem zdravilu sta citarabin in daunorubicin prisotna v obliki drobnih delcev, ki jih imenujemo „liposomi“.
English: The liposomes are expected to remain in the patient's body for longer than conventional cytarabine and daunorubicin medicines and to build up in the patient's bone marrow.
Slovenian: Liposomi naj bi v bolnikovem telesu ostali dlje kot zdravila z običajnimi oblikami citarabina in daunorubicina in naj bi se kopičili v bolnikovem kostnem mozgu.
English: Vyxeos is a cancer medicine used to treat adults with newly diagnosed acute myeloid leukaemia, a cancer of white blood cells.
Slovenian: Zdravilo Vyxeos je zdravilo za zdravljenje raka, ki se uporablja pri odraslih z novo diagnosticirano akutno mieloično levkemijo (AML), rakom belih krvnih celic.
English: How is Vyxeos used?
Slovenian: Kako se zdravilo Vyxeos uporablja?
English: Vyxeos improved survival compared with conventional cytarabine and daunorubicin in patients with acute myeloid leukaemia who have a poor prognosis and few alternatives.
Slovenian: Zdravilo Vyxeos je pomagalo pri daljšem preživetju v primerjavi z običajnimi oblikami citarabina in daunorubicina pri bolnikih z akutno mieloično levkemijo, ki imajo slabo prognozo in malo možnosti zdravljenja.
English: For the full list of side effects and restrictions with Vyxeos, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Vyxeos glejte navodilo za uporabo.
English: How does Vyxeos work?
Slovenian: Kako zdravilo Vyxeos deluje?
English: Vyxeos is given by infusion (drip) into a vein.
Slovenian: Zdravilo Vyxeos se daje z infundiranjem (kapalno infuzijo) v veno.
English: The study compared Vyxeos with conventional cytarabine and daunorubicin infusions.
Slovenian: V študiji so primerjali zdravilo Vyxeos z infuzijami z običajnimi oblikami citarabina in daunorubicina.
English: The active substances in Vyxeos are daunorubicin and cytarabine.
Slovenian: Učinkovini v zdravilu Vyxeos sta daunorubicin in citarabin.
English: The doctor may delay doses or stop treatment if the patient has severe side effects.
Slovenian: Če se pri bolniku pojavijo resni neželeni učinki, se lahko zdravnik odloči, da preloži odmerjanje ali ukine zdravljenje.
English: The dose is calculated based on the patient's height and weight; the infusion is given over 90 minutes on days 1, 3 and 5 of an initial treatment course; if the disease responds and the doctor considers further courses would be of benefit, Vyxeos is given on days 1 and 3 of each further course.
Slovenian: Če je opazen odziv na zdravljenje in zdravnik oceni, da bi bili koristni dodatni krogi zdravljenja, se zdravilo Vyxeos daje na prvi in tretji dan vsakega nadaljnjega kroga.
English: Vyxeos has been shown to improve how long patients lived in one main study involving 309 patients with high-risk acute myeloid leukaemia linked to previous treatment or associated with myelodysplasia.
Slovenian: V eni glavni študiji, ki je vključevala 309 bolnikov z visokim tveganjem za akutno mieloično levkemijo, povezano s predhodnim zdravljenjem ali z mielodisplazijo, so dokazali, da se z zdravilom Vyxeos življenjska doba bolnikov podaljša.
English: Czech Republic Orion Corporation
Slovenian: Češka republika Orion Corporation
English: Chemipharm S.G. De Tchaves & Cie E.E
Slovenian: De Tchaves & Cie E.E
English: United Kingdom Cipla (Eu) Limited
Slovenian: Cipla (Eu) Limited
English: Norway
Slovenian: Norveška
English: Estonia
Slovenian: Estonija
English: Czech Republic Ebewe Pharma
Slovenian: Češka republika Ebewe Pharma
English: Luxembourg Teva Pharma Belgium N.V./S.A
Slovenian: Luksemburg Teva Pharma Belgium N.V./S.A
English: Luxembourg Pfizer S.A. (Belgium)
Slovenian: Luksemburg Pfizer S.A. (Belgium)
English: Belgium Teva Pharma Belgium N.V./S.A
Slovenian: Teva Pharma Belgium N.V./S.A
English: United Kingdom Hameln Pharmaceuticals Ltd Methotrexate Hameln
Slovenian: Hameln Pharmaceuticals Ltd Methotrexate Hameln
English: Belgium Pfizer S.A. (Belgium)
Slovenian: Pfizer S.A. (Belgium)
English: Latvia
Slovenian: Latvija
English: United Kingdom Pfizer Limited
Slovenian: Pfizer Limited
English: Italy
Slovenian: Italija
English: Romania
Slovenian: Romunija
English: Iceland
Slovenian: Islandija
English: Sweden
Slovenian: Švedska
English: Portugal
Slovenian: Portugalska
English: Netherlands Mylan B.V.
Slovenian: Nizozemska Mylan B.V.
English: Poland
Slovenian: Poljska
English: Greece
Slovenian: Grčija
English: Ireland
Slovenian: Irska
English: Finland
Slovenian: Finska
English: France
Slovenian: Francija
English: Netherlands Centrafarm B.V.
Slovenian: Nizozemska Centrafarm B.V.
English: Czech Republic Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
Slovenian: Češka republika Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
English: Spain
Slovenian: Španija
English: Austria
Slovenian: Avstrija
English: Croatia
Slovenian: Hrvaška
English: Netherlands Teva Nederland B.V.
Slovenian: Nizozemska Teva Nederland B.V.
English: Belgium Sandoz N.V.
Slovenian: Sandoz N.V.
English: Lithuania
Slovenian: Litva
English: Netherlands Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
Slovenian: Nizozemska Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
English: Hungary
Slovenian: Madžarska
English: Netherlands Teva Pharma B.V.
Slovenian: Nizozemska Teva Pharma B.V.
English: Germany
Slovenian: Nemčija
English: Netherlands Addenda Pharma S.R.L.
Slovenian: Nizozemska Addenda Pharma S.R.L.
English: Belgium Aurobindo Pharma B.V.
Slovenian: Aurobindo Pharma B.V.
English: Slovakia
Slovenian: Slovaška
English: Netherlands Aurobindo Pharma B.V.
Slovenian: Nizozemska Aurobindo Pharma B.V.
English: Netherlands Sandoz B.V.
Slovenian: Nizozemska Sandoz B.V.
English: Netherlands Nordic Group B.V.
Slovenian: Nizozemska Nordic Group B.V.
English: Denmark
Slovenian: Danska
English: Bulgaria
Slovenian: Bolgarija
English: Netherlands Pharmachemie B.V
Slovenian: Nizozemska Pharmachemie B.V
English: Slovenia
Slovenian: Slovenija
English: Methotrexate Ebewe
Slovenian: Methotrexat ”ebewe”
English: Czech Republic Accord Healthcare Limited Injexate
Slovenian: Češka republika Accord Healthcare Limited Injexate
English: Epidural Use | Intrabursal Use | Intracoronary Use | Intradiscal Use | Intramuscular Use | Intravenous Use | Perineural Use| Retrobulbar Use
Slovenian: Emthexate injekcija epiduralna uporaba | intrabursalna uporaba | intrakoronarna uporaba | intradiskalna uporaba | intramuskularna uporaba | intravenska uporaba | perinevralna uporaba | retrobulbarna uporaba
English: Methotrexate Disodium 16.44mg Tablet
Slovenian: Mtx dinatrijev metotreksat 16,44 mg tableta tableta peroralna uporaba
English: Accord Healthcare Limited Инжексат Accord Methotrexate 15mg/0.3ml
Slovenian: Accord Healthcare Limited Инжексат Accord metotreksat 15 mg/0,3 ml
English: Метожект Pen Methotrexate 30mg/0.6ml
Slovenian: Метожект Pen metotreksat 30 mg/0,6 ml
English: Metotrexato Pfizer Methotrexate 1g Bottle Solution For Injection Intraarterial Use | Intramuscular Use | Intrathecal Use |
Slovenian: Metotrexato Pfizer metotreksat 1 g steklenička raztopina za injiciranje intraarterijska uporaba | intramuskularna uporaba | intratekalna uporaba | intravenska uporaba
English: Accord Healthcare Limited Methotrexat Accord Methotrexate 10mg Tablet
Slovenian: Accord Healthcare Limited Methotrexate Accord Healthcare metotreksat 10 mg tableta tableta peroralna uporaba
English: Метожект Pen Methotrexate 12.5mg/0.25ml
Slovenian: Метожект Pen metotreksat 12,5 mg/0,25 ml
English: Metotrexat Astron Methotrexate 30mg/0.6ml
Slovenian: Metotrexat Astron metotreksat 30 mg/0,6 ml
English: Intravenous Use
Slovenian: Afslamet intravenska uporaba
English: Метожект Pen Methotrexate 22.5mg/0.45ml
Slovenian: Метожект Pen metotreksat 22,5 mg/0,45 ml
English: Netherlands Accord Healthcare Limited Injexate
Slovenian: Nizozemska Accord Healthcare Limited Injexate
English: Methotrexate Orion Methotrexate 25mg Tablet
Slovenian: Methotrexate Orion metotreksat 25 mg tableta tableta peroralna uporaba
English: Метожект Pen Methotrexate 20mg/0.4ml
Slovenian: Метожект Pen metotreksat 20 mg/0,4 ml
English: Метожект Pen Methotrexate 10mg/0.2ml
Slovenian: Метожект Pen metotreksat 10 mg/0,2 ml
English: Metotrexat Astron Methotrexate 12.5mg/0.25ml
Slovenian: Metotrexat Astron metotreksat 12,5 mg/0,25 ml
English: Metotrexat Astron Methotrexate 20mg/0.4ml
Slovenian: Metotrexat Astron metotreksat 20 mg/0,4 ml
English: Metotrexat Astron Methotrexate 17.5mg/0.35ml
Slovenian: Metotrexat Astron metotreksat 17,5 mg/0,35 ml
English: Solution For Injection Intravenous Use
Slovenian: raztopina za injiciranje intravenska uporaba
English: Метожект Pen Methotrexate 17.5mg/0.35ml
Slovenian: Метожект Pen metotreksat 17,5 mg/0,35 ml
English: Метожект Pen Methotrexate 27.5mg/0.55ml
Slovenian: Метожект Pen metotreksat 27,5 mg/0,55 ml
English: Метожект Pen Methotrexate 15mg/0.3ml
Slovenian: Метожект Pen metotreksat 15 mg/0,3 ml
English: Metotrexato Wyeth Methotrexate 2.5mg Tablet
Slovenian: Metotrexato Wyeth metotreksat 2,5 mg tableta tableta peroralna uporaba